📊 CPIX Key Takeaways
Investment Thesis
Cumberland Pharmaceuticals is unprofitable with negative operating and net margins (-6.3% and -6.4% respectively), though revenue growth of 17.6% YoY shows some market traction. While the company generates positive free cash flow of $4.8M, weak liquidity (current ratio 1.01x) and continued negative returns on equity (-11.4%) indicate operational challenges that outweigh growth potential.
CPIX Strengths
- Revenue growth of 17.6% year-over-year demonstrates market demand and potential expansion
- Positive free cash flow of $4.8M with 10.9% FCF margin provides some financial flexibility
- Low leverage with 0.00x debt-to-equity ratio reduces financial distress risk
- Significant insider activity with 15 Form 4 filings suggests management engagement
CPIX Risks
- Persistent unprofitability with negative net income of -$2.8M and net margin of -6.4%
- Weak liquidity position with current ratio of 1.01x and quick ratio of 0.84x creates cash flow vulnerability
- Negative returns on equity (-11.4%) and ROA (-3.7%) indicate inefficient asset utilization and shareholder value destruction
- Negative interest coverage ratio of -5.6x reflects inability to cover obligations from operating results
- Operating margin of -6.3% suggests structural profitability challenges despite revenue growth
Key Metrics to Watch
- Path to operating profitability and margin expansion
- Cash burn rate and sustainability of free cash flow generation
- Liquidity improvement through working capital optimization
- Revenue growth sustainability and product pipeline effectiveness
CPIX Financial Metrics
💡 AI Analyst Insight
CUMBERLAND PHARMACEUTICALS INC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CPIX Profitability Ratios
CPIX vs Healthcare Sector
How CUMBERLAND PHARMACEUTICALS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CPIX Balance Sheet & Liquidity
CPIX 5-Year Financial Trend
5-Year Trend Summary: CUMBERLAND PHARMACEUTICALS INC's revenue has grown significantly by 24% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
CPIX Growth Metrics (YoY)
CPIX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.3M | -$1.4M | $-0.10 |
| Q2 2025 | $9.8M | $516.3K | $0.03 |
| Q1 2025 | $8.5M | $1.3M | $0.08 |
| Q3 2024 | $9.1M | $15.1K | $0.00 |
| Q2 2024 | $9.8M | $872.2K | $0.06 |
| Q1 2024 | $8.5M | $192.2K | $0.01 |
| Q3 2023 | $10.1M | $15.1K | N/A |
| Q2 2023 | $10.3M | $872.2K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CPIX Capital Allocation
CPIX SEC Filings
Access official SEC EDGAR filings for CUMBERLAND PHARMACEUTICALS INC (CIK: 0001087294)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 20, 2026 | 4 | xslF345X06/wk-form4_1774041843.xml | View → |
| Mar 20, 2026 | 4 | xslF345X06/wk-form4_1774041820.xml | View → |
| Mar 20, 2026 | 4 | xslF345X06/wk-form4_1774041759.xml | View → |
| Mar 20, 2026 | 4 | xslF345X06/wk-form4_1774041719.xml | View → |
| Mar 20, 2026 | 4 | xslF345X06/wk-form4_1774041699.xml | View → |
❓ Frequently Asked Questions about CPIX
What is the AI rating for CPIX?
CUMBERLAND PHARMACEUTICALS INC (CPIX) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPIX's key strengths?
Revenue growth of 17.6% year-over-year demonstrates market demand and potential expansion. Positive free cash flow of $4.8M with 10.9% FCF margin provides some financial flexibility.
What are the risks of investing in CPIX?
Persistent unprofitability with negative net income of -$2.8M and net margin of -6.4%. Weak liquidity position with current ratio of 1.01x and quick ratio of 0.84x creates cash flow vulnerability.
What is CPIX's revenue and growth?
CUMBERLAND PHARMACEUTICALS INC reported revenue of $44.5M.
Does CPIX pay dividends?
CUMBERLAND PHARMACEUTICALS INC does not currently pay dividends.
Where can I find CPIX SEC filings?
Official SEC filings for CUMBERLAND PHARMACEUTICALS INC (CIK: 0001087294) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPIX's EPS?
CUMBERLAND PHARMACEUTICALS INC has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.